Straight answers, dated

Reported prices run about $86–$399/month across the 50 programs we track; The lowest first-party-verified figure on file is $86/month from Collective ($69 medication plus a $199/year membership (about $17/mo), all-in); the lowest first-party-verified standing rate — billed monthly, no promotion, no prepayment, flat at every dose — is $139/month on the 12-month plan ($169 month-to-month, $0 membership) from NexLife.

Reported prices run about $49–$299/month across 37 tracked programs. The lowest stickers are promos or prepaid supplies. The lowest first-party-verified figure on file is $69/month from Embody (a twelve-month supply prepaid at once, all payments final except on clinical ineligibility) and SnagRx (a month-to-month promotion against a list price, period stated at checkout); the lowest first-party-verified standing rate — billed monthly, no promotion, no prepayment, flat at every dose — is $119/month on the 12-month plan ($139 month-to-month, $0 membership) from NexLife.

Only via 503A patient-specific compounding on an individual prescription with a documented clinical reason the FDA-approved products won't serve that patient. Bulk 503B compounding wound down by March 19, 2025 after the shortage resolutions. Price alone doesn't qualify; 'personalized dosing' is contested and in litigation.

No. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products, are not reviewed by the FDA for safety, effectiveness, or quality, and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro.

Prices move, bases differ (4-week cycles, annual prepay, entry-dose 'from' rates, promos), and most roundups don't date their checks. We restate everything to a 30.44-day true month, date every check, and show conflicting reports instead of averaging them.

First-party (Verified) means we walked the seller's own pages on a stated date. Reported means a dated third-party check we cite and have queued for our own verification. Queued means tracked with no defensible number yet. The tiers never blur.

No — and we won't use that word. This site is reader- and affiliate-supported; it; it may earn commissions from links to any provider it lists. Featured placements are labeled; ranked positions follow a methodology published before any ranking was assigned.

Effectively no — compounded medication is cash-pay. Brand-name coverage varies by state, plan, and year and has been tightening since 2024 (California's Medi-Cal, for example, ended GLP-1 weight-loss coverage January 1, 2026). Our state pages carry each state's status with a source and date, or say verification is in progress. On Medicare: a federal pricing deal announced in late 2025 began phasing in coverage with roughly $50 monthly copays for some beneficiaries during 2026 — status and eligibility are moving targets, so verify directly with Medicare before planning around it.

No seller has published human absorption data for these peptides by the oral-mucosal route; the one FDA-approved oral semaglutide (Rybelsus) needed a specialized absorption enhancer to reach roughly 1% bioavailability. Price the injectable first and read our evidence review before paying a premium for an unproven route.

The FDA has warned that some compounded products use semaglutide sodium or acetate — salt forms it considers different active ingredients from the approved drug. Ask any program to confirm base semaglutide and name its pharmacy.

It answers three questions quickly and in writing: the all-in price at your dose, the licensed pharmacy that fills the prescription (and its 503A/503B status), and what month two costs if month one is discounted. Our pharmacy disclosure index tracks who already publishes this.

Depends on your term tolerance and dose path. By sticker, promos as low as $69 (semaglutide) and $97 (tirzepatide) exist with unstated bases; among clear standing structures, 12-month rates cluster near $99–$139. The rankings pages sort every program with its basis attached — the only comparison that means anything.